

Supplementary Table 7. Baseline Characteristics of Patients with a Confirmed Diagnosis of Ulcerative Colitis by Second Line Treatment

Characteristic	Adalimumab (n = 86)	Infliximab (n = 129)	Golimumab (n = 114)	Vedolizumab (n = 125)	Ustekinumab (n = 124)	Tofacitinib (n = 106)	Filgotinib (n = 10)
Sex							
Male	51 (59.3)	96 (74.4)	63 (55.3)	85 (68.0)	86 (69.4)	68 (64.2)	6 (60.0)
Female	35 (40.7)	33 (25.6)	51 (44.7)	40 (32.0)	38 (30.6)	38 (35.8)	4 (40.0)
Age at commencement of second line (yr)							
Mean ± SD	37.6 ± 13.0	39.7 ± 14.6	41.5 ± 12.8	40.9 ± 13.3	39.8 ± 13.9	38.6 ± 12.5	37.4 ± 11.6
Median (IQR)	38 (27–46)	39 (27–52)	42 (31–51)	43 (30–52)	41 (27–51)	39 (27–49)	42 (27–46)
Charlson Comorbidity Index							
Mean ± SD	0.74 ± 1.00	0.99 ± 1.20	0.85 ± 0.90	1.17 ± 1.70	0.96 ± 1.50	0.91 ± 1.30	0.70 ± 0.90
Median (IQR)	0 (0–1)	1 (0–1)	1 (0–1)	1 (0–2)	1 (0–1)	0 (0–2)	0.5 (0–1)
0	46 (53.5)	53 (41.1)	51 (44.7)	56 (44.8)	57 (46.0)	55 (51.9)	5 (50.0)
1–2	35 (40.7)	63 (48.8)	58 (50.9)	55 (44.0)	55 (44.4)	41 (38.7)	4 (40.0)
3–5	5 (5.8)	11 (8.5)	5 (4.4)	10 (8.0)	10 (8.1)	9 (8.5)	1 (10.0)
>5	0	2 (1.6)	0	4 (3.2)	2 (1.6)	1 (0.9)	0
Hospitalizations within 6 mo prior to second line							
Yes	15 (17.4)	65 (50.4)	28 (24.6)	25 (20.0)	24 (19.4)	29 (27.4)	0
No	71 (82.6)	64 (49.6)	86 (75.4)	100 (80.0)	100 (80.6)	77 (72.6)	10 (100.0)
Time from first- to second line (day)							
Mean ± SD	467.3 ± 404.6	240.8 ± 322.8	446.4 ± 487.4	473.4 ± 468.3	537.6 ± 646.5	385.8 ± 465.2	733.0 ± 324.9
Median (IQR)	317 (196–672)	143 (72–284)	267 (154–576)	308 (126–665)	326 (145–608)	180 (84–497)	714 (413–1,074)

Values are presented as number (%) unless otherwise indicated. SD, standard deviation; IQR, interquartile range.